BD hit with FDA warning related to Pyxis medication management
Dec 23, 2024 · The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of its $12 billion CareFusion acquisition in 2015.. The warning letter, dated Nov. 22 and posted on Dec. 17, involves inspections conducted in May at a former CareFusion facility in San Diego.
Insulet fully launches Omnipod 5 app for iPhone in U.S.
Oct 29, 2024 · The Omnipod 5 with the Dexcom G7 CGM. [Image courtesy of Insulet] Insulet (Nasdaq:PODD) today announced the full market release of the Omnipod 5 automated insulin delivery app for iPhone in the U.S. Acton, Massachusetts-based Insulet now offers the app for free download from the Apple App Store.
These diabetes devices are set to launch in 2024 - Drug Delivery …
Feb 27, 2024 · The Stelo glucose monitor for people with diabetes who are not taking insulin. [Image courtesy of Dexcom] The diabetes space continues to innovate, and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year. At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year.Some of those stories didn’t end in 2023, though ...
The 9 largest diabetes technology companies in the world
Aug 21, 2024 · Technologies from Abbott, Dexcom, Medtronic and Insulet. These companies are the four largest diabetes technology companies in the world. [Images courtesy of the companies] Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in …
Vivani Medical initiates first-in-human GLP-1-eluting implant study
Dec 19, 2024 · The Vivani NanoPortal technology. [Image courtesy of Vivani] Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects.
ARS Pharmaceuticals wins first FDA nod for nasal epinephrine
Aug 12, 2024 · neffy nasal epinephrine. [Image courtesy of ARS Pharmaceuticals] ARS Pharmaceuticals (Nasdaq:SRPY) announced that it received FDA approval for its neffy (epinephrine nasal spray) 2 mg for treating of Type I allergic reactions. Approval includes the treatment of anaphylaxis, with the indication covering …
CeQur wins FDA nod for mealtime insulin delivery device
Jul 1, 2024 · The CeQur Simplicity wearable insulin delivery device. [Image courtesy of CeQur] CeQur announced recently that the FDA granted 510(k) clearance for its Simplicity system for an extended wear duration. Clearance extends the wear time for the wearable mealtime insulin delivery patch from three to four days.
Insulet integrates Omnipod 5 with Abbott Libre 2 Plus in U.S.
Nov 20, 2024 · The Omnipod 5 with the Abbott FreeStyle Libre 2 Plus. [Image courtesy of Insulet] Insulet (Nasdaq:PODD) today announced compatibility between its Omnipod 5 insulin pump and the Abbott (NYSE:ABT) FreeStyle Libre 2 Plus CGM in the U.S. The company says this latest integration makes Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S. Compatibility in the U.S. comes ...
PreEvnt to unveil non-invasive blood glucose alert device
Jan 3, 2025 · The Isaac blood glucose alert device. [Image courtesy of PreEvnt] PreEvnt recently announced plans to introduce Isaac, its non-invasive alert device for monitoring blood glucose levels. Isaac, which is meant to monitor blood glucose levels using just the breath of the user, also has a custom phone app.
FDA approves next-gen drug delivery system from Medtronic
Oct 10, 2023 · The SynchroMed III system. [Image courtesy of Medtronic] Medtronic (NYSE:MDT) announced today that the FDA approved its next-generation SynchroMed III intrathecal drug delivery system. The medtech giant designed SynchroMed III to treat patients with chronic pain, cancer pain and severe spasticity.